FOXP2 AS A MASTER REGULATOR OF BASAL-LIKE BREAST CANCER INITIATION AND PROGRESSION AND A NOVEL TARGET FOR ANTINEOPLASTIC THERAPY
$1,213,486FY2015Department of the ArmyDOD
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc.